Liposomal antibiotic formulation

Details Liposomal antibiotic formulation Liposomal antibiotic formulation

A - Human Necessities

61

K

A61K 47/24 (2006.01) A61K 9/127 (2006.01) A61K 31/54 (2006.01)

Patent

CA 2117046

The drugs of choice for treating intra-abdominal sepsis caused by infection with Gram negative bacteria include .beta.-lactams such as cefoxitin. However, unless the drugs are administered within 8 to 12 hours post-infection, the infecting microbes rapidly gain entry to and reside in cells of the reticuloendothelial system, where the microbes appear to become shielded from further drug action. It has been found that a liposomal cefoxitin formulation is effective in reducing the bacterial counts and the mortality of animals suffering from intra-abdominal Gram negative sepsis. The preferred liposome is phosphatidylcholine and phosphatidylserine in the molar ratio of from 9.5:0.5 to 1:1.

Affiliated with

Also associated with

Rating

Liposomal antibiotic formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Liposomal antibiotic formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liposomal antibiotic formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1518714